Search Results 521-530 of 24198 for In situ

1. CATALINA-2: A Clinical Study Of TORL-1-23 In Platinum-resistant Ovarian Cancer.

   Participants with malignancies with a low risk of recurrence, including appropriately treated ductal carcinoma in situ of the breast are not excluded. 13 ...

2. Clinical trials - Oncology (Medical)

   ... in treating patients with HER2 expressing ductal carcinoma in situ. H2NVAC is a vaccine designed to stimulate specialized white blood cells in hopes of ...

3. Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary - Mayo Clinic

   Carboplatin, Paclitaxel, and Everolimus in ... RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in ... situ of the cervix; NOTE: if ...

4. SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab - Mayo Clinic

   The primary objective of this study is to determine the safety profile of SX-682 alone and in ... in situ of the prostate, cervix, or breast. Subjects with active ...

5. Vedolizumab IV in Pediatric Participants With Ulcerative Colitis or Crohn's Disease - Mayo Clinic

   ... in situ that has been adequately treated and that has not recurred for at least 3 years prior to first dose of study drug. Participants with remote history ...

6. Study of Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder - Mayo Clinic

   EBV positive by Epstein-Barr virus early ribonucleic acid (RNA) (EBER) in situ hybridization (preferred) and/or LMP immunoperoxidase staining. There must be ...

7. AMG 181 in Subjects with Moderate to Severe Crohn's Disease - Mayo Clinic

   Subject has malignancy (other than resected cutaneous basal or cutaneous squamous cell carcinoma, or treated in situ cervical cancer considered cured) within 5 ...

8. A 52-week Study Of Rilzabrutinib Efficacy And Safety Compared To Placebo In Adults Diagnosed With IgG4-related Disease - Mayo Clinic

   A 52-week Study Of Rilzabrutinib Efficacy And Safety Compared To Placebo In Adults Diagnosed With IgG4-related Disease ... situ carcinoma of the cervix, ...

9. Study Of Sacituzumab Govitecan-hziy And Pembrolizumab Versus Treatment Of Physician's Choice In Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery And Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) - Mayo Clinic

   ... in situ hybridization (ISH)). * Adequate excision and surgical removal of all clinically evident of disease in the breast and/or lymph nodes and have ...

10. Comparison of Operation to Monitoring With/Without Endocrine Therapy For Low Risk DCIS - Mayo Clinic

    Our overarching hypothesis is that management of low-risk Ductal Carcinoma in Situ (DCIS) using an AS approach does not yield inferior cancer or quality of life ...